Citations

Clear

21 citation(s) found for "Shehab, M".

Climate stressors and impact on cardio-oncology burden in the united states: nationwide and geographically matched analyses
Hassan, I, Kurasz, A, Aldalaeen, R, Alhammouri, H, Alasmar, R, Saif, R, Ibrahim, M, Alghzlawi, I, Shehab, M, Rafaat, K, Kuzma, L, Abohashem, S, Hassan, Ibrahim , Hassan, Ibrahim, Kurasz, Anna , Aldalaeen, Raneem, Al-Asmar, Rahmeh , SAIF, RIYADH, Alghzlawi, Ibrahim , Raafat, Kareem Wael , Kuzma, L, Abohashem, Shady

Mayo Clinic

European Journal of Preventive Cardiology | June 11, 2026 | Volume: 33 | Issue: Supplement_2 | Pages: No page available

10.1093/eurjpc/zwag249.289 Get It

Abstract Background Climate-related stressors such as heat, wildfires, and extreme weather are increasingly recognized as determinants of cardiovascular and oncologic health. However, their joint impact on overlapping cancer–cardiovascular disease (CVD) burdens remains unknown. We developed a Cardio-Oncology Burden Index (COBI) to quantify the co-prevalence of cancer and CVD at the community level and examined its association with climate vulnerability across U.S. census tracts. Methods We conducted a cross-sectional ecological analysis of 82,679 census tracts (328,683,841 residents) using the CDC PLACES database. COBI was derived using principal component analysis of age-adjusted prevalence of cancer, coronary artery disease, and stroke. The Climate Burden Index (CBI, 0–1 percentile) integrates multiple climate-related exposures, including extreme temperature, wildfire frequency, and severe weather events. Population-weighted mixed-effects regression models with county-level random effects estimated associations between CBI and COBI, adjusting for region, rurality, and environmental justice indicators. β coefficients represent percentage-point differences in COBI per unit (or category) increase in climate burden. Exposure–response relationships were examined using restricted cubic splines (RCS). Robustness was assessed via geographically matched (<50 km) and fully matched (region, rural–urban commuting area, and environmental justice) analyses. Results Marked spatial heterogeneity was observed in both CBI and COBI across the U.S. (Fig. A–B). Higher climate burden was consistently associated with greater cardio-oncology burden (Fig. C), demonstrating a dose–response relationship: second vs lowest quartile β=0.92 (95% CI, 0.61–1.24); third vs lowest quartile β=1.61 (95% CI, 1.30–1.92); highest vs lowest quartile β=3.44 (95% CI, 3.11–3.76). The RCS model revealed a significant non-linear association (p_non-linear<0.001), with a plateau at moderate exposures and a steep rise at the highest CBI levels (Fig. D). Results remained robust in sensitivity analyses (β=4.17 [95% CI, 3.62–4.71] for geographically matched; β=4.39 [95% CI, 4.10–4.69] for fully matched tracts; Table). Conclusions Greater climate burden is independently associated with higher cardio-oncology burden across U.S. communities, with disproportionate effects in the most climate-vulnerable areas. This novel, population-level linkage between climate stress and onco-cardiovascular disease burden, highlights an emerging syndemic at the intersection of environment, cancer, and CVD. Targeted mitigation and prevention strategies integrating environmental resilience into chronic disease prevention are urgently needed.For image description, please refer to the figure legend and surrounding text.
The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials
Goodwin, Shane W. , Yuan, Yuhong , Singh, Siddharth, Solitano, Virginia , Bose, Rishabh , Shehab, Mohammad , Narula, Neeraj , Ma, Christopher, Ahuja, Vineet , Ahuja, Vineet , Narula, Neeraj , Jairath, V , Solitano, Virginia , Singh, S , Vuyyuru, Sudheer K. , Jairath, Vipul , Ahuja, Vineet

Mayo Clinic

Journal of Crohn's and Colitis | June 1, 2026 | Volume: 20 | Issue: 6 | Pages: No page available

10.1093/ecco-jcc/jjag081 | PMID 42357952 Get It

Abstract Introduction Despite progress in understanding placebo effects in clinical trials of inflammatory bowel disease (IBD), there is a limited understanding of how socioeconomic factors of recruiting countries impact placebo rates. We investigated the association of socioeconomic factors across recruitment sites on placebo rates in IBD randomized controlled trials. Methods We examined the association of clinical and endoscopic remission and response to the weighted Gross National Index (GNI) per capita, Human Development Index (HDI), and out-of-pocket health expenditures as a percentage of current health expenditures (OOP_CHE) of identified trials using mixed effects linear regression. Results Across 76 trials (Crohn’s disease [CD]: n = 32; ulcerative colitis [UC]: n = 44), placebo response rates over time were largely stable, with a small increase across time in clinical remission for CD trials (β = 0.4% per increase in study year, 95% CI: 0.3%-0.84%, P = .04) and a small decrease across time in endoscopic response for UC trials (β = −1.39% per increase in study year, 95% CI: −1.79, −0.99, P < .001). Clinical response was most susceptible to changes in socioeconomic factors in IBD trials (β = −2.96% per 10 000 USD increase in study GNI, 95% CI: −4.98, −0.95%, P = .004; P < .05 for HDI and OOP_CHE). Across both conditions, decreases in clinical response were associated with increases in HDI and OOP_CHE (CD HDI: β = −1.15% per 0.01 increase in study HDI, 95% CI: −2.24, −0.06%, P = .04; UC HDI: β = −0.66% per 0.01 increase in study HDI, 95% CI: −1.19, −0.12%, P = .02). Discussion We found that placebo clinical response was most susceptible to influences of site-level socioeconomic wellbeing. These findings highlight that estimation of placebo rates in trial planning should account for geographic location of recruiting sites.
Clinicopathologic characteristics of somatic TP53 mutations in Philadelphia chromosome–negative myeloproliferative neoplasms: A systematic review and pooled analysis.
Aldapt, Mahmood, Saleh, Ahmed, Najim, Mostafa, Salem, Ahmad, Al-Mashdali, Abdulrahman, Muthanna, Bassam , Aweer, Ruba, Rabadi, Marrita , Mohamed, Shehab F., Aweer, Ruba Adel , Aldapt, Mahmood, Kaddoura, Rasha , Al-Mashdali, Abdulrahman F , Mohamed, Shehab Fareed

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e18597 Get It

e18597 Background: TP53 mutations ( TP53 m) are uncommon in chronic-phase (CP) Philadelphia (Ph) chromosome–negative myeloproliferative neoplasms (MPN) but are increasingly reported in myelofibrosis (MF) and accelerated/blast phase (AP/BP). Their distribution, allelic configuration, and associated clinical outcomes have not been systematically synthesized. Methods: A PRISMA-guided search of EMBASE and PubMed (1974-July 1, 2025) identified cohort studies reporting adult Ph–negative MPNs with molecularly confirmed TP53 m. Case reports were excluded; Conference abstracts were included if cohort-level data were available. Extracted variables included demographics, MPN subtype, disease phase, TP53 allelic status (per International Consensus Classification), variant allele frequency (VAF), allogeneic hematopoietic cell transplantation (allo-HCT), median overall survival (mOS), and leukemic transformation. Given heterogeneity and lack of comparators, pooled proportions with (95% CI) were generated for descriptive variables; outcomes were summarized descriptively. Results: 10 retrospective studies met inclusion criteria. Pooled mean age was 61 years (95% CI 57.18–65.17) with male predominance (58%, 95 CI 53–63). TP53 m were uncommon in patients with Ph-negative MPN (3%, 95% CI 0–15%) but were higher in MF/AP/BP (10%, 95% CI 4–24%). Among patients with TP53 m, disease distribution included MF (35%, 95% CI 13–65%), AP/BP (33%, 95% CI 26–41%), essential thrombocythemia (ET) (10%, 95% CI 3–28%), and polycythemia vera (PV) (8%, 95% CI 4–14%). Multi-hit TP53 m accounted for 52% (95% CI 40–64%), while single-hit comprised 47% (95% CI 34–60%). The pooled mean TP53 VAF was 37.48% (95% CI 30.73–44.24%). Allo-HCT was used in 16% (95% CI 13–20%). One cohort reported leukemic transformation in 47% with a median follow-up of 9.6 months (m). Reported mOS in TP53 m CP-MF ranged from 11.6–18 m and was not reached in PV/ET, whereas AP/BP mOS ranged from 4.5–6 months. Conclusions: TP53 m Ph–negative MPNs are enriched in MF and AP/BP and frequently demonstrate multi-hit TP53 m with high VAF and associated with high leukemic transformation. Standardized molecular reporting and prospective studies are needed to refine prognostication and treatment strategies in TP53m MPN. Characteristics of patients with TP53 m MPN. Variable Pooled variables (95% CI) Age 61.18 years (57.18–65.17) Male/Female 58% (53–63)/42% (53–63) TP53 mutation in the cohort 3% (0–15) TP53 in MF/AP/BP 10% (CI 4–24) Primary myelofibrosis 35% (13–65) MPN in AP/BP 33% (26–41) Essential thrombocythemia 10% (CI 3–28) Polycythemia vera 8% (CI 4–14) Multi-hit/single-hit TP53 52% (CI 40–64) 47% (CI 34–60) TP53 VAF 37.48% (30.73–44.24) Abbreviations: MF: Myelofibrosis, AP: accelerated phase, BP: Blast phase, MPN: myeloproliferative neoplasm, VAF: Variant Allele Frequency.
Pregnancy in women with myelodysplastic syndromes: a scoping review of maternal, obstetric, and neonatal outcomes
Mohamed, Shehab F., Alqatati, Fadel , Rabadi, Marrita , Tartour, Angham Ibrahim , Dalol, Ayman, Hekmat, Mymuna, Aweer, Ruba Adel , Al‐Mashdali, Abdulrahman , Abdulgayoom, Mohammed , Gangat, N, Dalol, Ayman , Al-Mashdali, Abdulrahman F , Abdulgayoom, Mohammed , Mohamed, Shehab Fareed , Benkhadra, Maria

Mayo Clinic

Leukemia & Lymphoma | April 16, 2026 | Volume: 67 | Issue: 6 | Pages: 1247-1256

10.1080/10428194.2026.2653811 | PMID 41989197 Get It

A Comprehensive 3D Look into Male and Female Facial Skeletons: AI-Assisted Analysis of 280 CT Scans
Hussein, S.H., Shehab, Abdallah A. , Rames, Jess D. , Pazelli, Alexandre Meira, Martinez, Erick O., Hanson, Christian R., Morris, Jonathan M. , Abu Shehab, Abdallah, Pazelli, Alexandre M., Sharaf, Basel

Mayo Clinic

Plastic & Reconstructive Surgery | February 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/prs.0000000000012920 | PMID 41677273 Get It

Background: Sexual dimorphism in the facial skeleton is fundamental to aesthetics and gender perception. This study employs AI-assisted three-dimensional (3D) imaging to analyze morphological differences between males and females in the upper, mid, and lower facial regions. Methods: A retrospective analysis was conducted on 280 high-resolution craniofacial CT scans (147 females, 133 males) of adults aged 20 years and older. AI-assisted segmentation and modeling were performed using Materialise Mimics and 3-Matic software. The facial skeleton was divided into upper, mid, and lower regions for detailed morphometric evaluation. Statistical shape modeling (SSM) and heatmaps were used to visualize surface projection differences across age groups. Statistical comparisons were conducted to assess gender-based variation. Results: Significant sexual dimorphism was observed across all facial regions. In the upper face, males had greater interorbital width, frontotemporal brow width, inter-medial canthi distance, and more prominent frontal bossing. In the midface, males exhibited increased width, depth, and vertical height, with the most pronounced differences occurring in middle age. The lower face showed larger mandibular dimensions in males, including bigonial width, ramus height, and a sharper mental angle, while females had a more rounded chin and smoother mandibular contour. Heatmaps confirmed greater surface projection in male skeletons, particularly in the gonial and midfacial regions, with dimorphism decreasing with age. Conclusion: This represents the first large-sample CT study utilizing AI to comprehensively quantify facial skeletal dimorphism. Findings support the importance of gender-specific planning in facial reconstructive and aesthetic procedures.
Plasmacytoid dendritic cell-associated acute myeloid leukemia (pDC-AML) a comprehensive review
Abdalla, Azza, Al‐Mashdali, Abdulrahman , Hilmi, Feryal, Gangat, Naseema , Soliman, Dina A. , Fareed, Shehab, Al-Mashdali, Abdulrahman F , Ravandi, Farhad , Soliman, Dina

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6925-6925

10.1182/blood-2025-6925 Get It

Abstract Background: Plasmacytoid dendritic cell-associated acute myeloid leukemia (pDC-AML) is an emerging, rare subtype of AML characterized by the clonal proliferation of plasmacytoid dendritic cells (pDCs) at various stages of maturation. Although infrequent, this leukemia subtype is clinically aggressive and poses significant diagnostic and therapeutic challenges. Objective: This review synthesizes current knowledge on the immunophenotypic, genetic, and clinical features of pDC-AML, explores its prognostic implications, and compares it with the related entity blastic plasmacytoid dendritic cell neoplasm (BPDCN). Methods: A comprehensive literature search was conducted using databases including PubMed, Scopus, and Web of Science. Studies describing the morphology, immunophenotype, cytogenetics, molecular alterations, clinical presentation, and treatment outcomes of pDC-AML were included. Data were extracted and compiled from 16 studies encompassing 231 patients. Results: pDC-AML predominantly affects older adults (median age ~69 years) and exhibits a male predominance (~68%). It presents with diverse AML subtypes, including AML with monocytic differentiation, minimal differentiation, and secondary AML. Bone marrow pDCs range from 2.2% to 30% and exhibit variable maturation, often expressing CD123, CD303, CD304, and variably CD34 and CD117. In contrast to BPDCN, CD56 is rarely expressed, and skin or lymph node involvement is uncommon. Genetically, pDC-AML exhibits a complex landscape. RUNX1 mutations are the most common (14–78%), possibly driving pDC lineage commitment. Additional mutations include ASXL1, DNMT3A, SRSF2, FLT3, and BCOR. Chromosomal abnormalities such as chromosome 7 deletions, trisomy 13, and MLL or CBFA rearrangements are frequently observed. Compared to BPDCN—which shows high CD56 and TCL1 expression and more frequent TET2 mutations—pDC-AML is more genetically and phenotypically heterogeneous. Therapeutic responses are inconsistent. Treatments include induction chemotherapy, hypomethylating agents (e.g., azacytidine plus venetoclax), and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Median overall survival ranges from 9.6 to 20 months, with frequent relapse even post-HSCT. Emerging therapies targeting CD123 (e.g., tagraxofusp) and immune-modulating agents are under investigation. Conclusion: pDC-AML is a clinically aggressive and biologically distinct AML subtype defined by clonal pDC expansion, frequent RUNX1 mutations, and suboptimal responses to current therapies. Accurate diagnosis relies on integrated immunophenotypic and genetic profiling. Despite progress, patient outcomes remain poor, underscoring the need for improved classification, prognostic markers, and targeted therapeutic strategies.
D154. Virtual Surgical Plaining in Craniomaxillofacial Surgery: What is the State Of Evidence?
Shehab, Abdallah A. , Michaelcheck, Charlotte E., Hussain, S., Hallak, Hana , Sharaf, Basel , Hussain, Sara, Gibreel, Waleed , Alser, Osaid H. , Morris, Jonathan M.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 16, 2025 | Volume: 13 | Issue: S2 | Pages: 158-159

10.1097/01.gox.0001115108.24452.e4 Get It

P11. Demystifying Facial Bony Changes With Aging: AI-assisted Analysis of 564 Faces
Hussein, S.H., Rames, Jess D. , Morris, Jonathan M. , Shehab, Abdallah A. , Pazelli, Alexandre Meira, Sharaf, Basel

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 16, 2025 | Volume: 13 | Issue: S2 | Pages: 49-50

10.1097/01.gox.0001114236.25889.79 Get It

How Does the Mandible Age? Comprehensive Artificial Intelligence–Assisted Shape Analysis in the White Population
Hussein, S.H., Rames, Jess D. , Shehab, Abdallah A. , Pazelli, Alexandre Meira, Sears, Victoria A. , Wentworth, Adam, Morris, Jonathan M. , Pazelli, Alexandre M., Sharaf, Basel

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 21, 2025 | Volume: 13 | Issue: 4 | Pages: e6650

10.1097/gox.0000000000006650 | PMID 40264908 Get It

Background: Mandible contour significantly influences facial appearance, framing the lower facial silhouette. Redefining mandibular contour is key for facial and neck rejuvenation. Yet, there is limited facial aging research across different lifespans and sexes. Here, we utilize artificial intelligence and advanced 3-dimensional (3D) analysis to elucidate mandibular aging patterns in male and female subjects. Methods: A retrospective analysis of facial computed tomography scans in White patients was conducted, categorizing subjects into 3 age groups (20–79 y) and stratifying them by sex. Artificial intelligence–assisted segmentation into 3D mandibles was done in Mimics v.25, and statistical shape modeling was used to create an average mandible for each group. Volume and linear measurements were assessed via 3D overlays. Results: Analysis of 280 mandibles demonstrated statistically significant aging changes in both sexes. Ramus height showed a marked decrease with age, by approximately 5.3 mm in women and 4.2 mm in men (P < 0.001). Interrami and intercondylar widths increased by a mean of 4–5 mm (P < 0.01). Women exhibited an increase in mandibular angle (P < 0.01), and bony resorption over the chin compared to men, who exhibited concentrated bone resorption at the gonion projection. Conclusions: Mandibular aging, independent of tooth loss, exhibits specific bone remodeling patterns by sex. Posteriorly, mandibular widths increase in both sexes, whereas ramus height decreases. Women experience more resorption at the anterior alveolar surface and chin than men. Statistical shape modeling effectively visualizes these patterns on a population level, bridging the gap between traditional aging research and current understanding.
Point-of-Care Virtual Planning and 3D Printing in Facial Trauma: A 10-Year Experience at a Single Institution
Hussein, S.H., Kuruoglu, Doga , Morris, Jonathan M. , Sears, Victoria A. , Shehab, Abdallah A. , Gibreel, Waleed , Hussein, Sara M , Sharaf, Basel A , Kuruoglu, Doga , Morris, Jonathan , Gibreel, Waleed , Sharaf, Basel

Mayo Clinic

Journal of Clinical Medicine | April 17, 2025 | Volume: 14 | Issue: 8 | Pages: 2788

10.3390/jcm14082788 | PMID 40283618 Get It

Background: Despite increased adoption of virtual surgical planning (VSP) in various craniofacial indications, the incorporation of VSP/3DP into facial trauma care remains limited. Therefore, Expedited Preoperative Point of Care for Fracture Reduction to Normalized Anatomy and 3DP to Improve Surgical Outcomes (EPPOCRATIS) was introduced in 2021. This study evaluates our experience with EPPORATIS in craniomaxillofacial trauma over 10 years. Methods: A retrospective review of patients who underwent facial trauma repair between September 2014 and September 2024 was conducted. For each VSP/3DP case, a patient with similar facial trauma patterns, who was treated without VSP, was selected. Evaluation metrics included operative time, blood loss, length of stay, complication rates, and fracture reduction accuracy through 3D heatmap analyses. Operative metrics were normalized by implant (i.e., fracture plates and screws) count to account for fracture complexity. A value of p < 0.05 was deemed statistically significant. Results: The VSP group presented with more complex injuries and higher involvement of various surgical specialties (p < 0.5) and demonstrated longer operative times (p < 0.03). Although the difference was not statistically significant (p = 0.4), when adjusted for implant count, the VSP group had shorter operative times (median: 15.4 vs. 19.3 min/implant) and reduced blood loss compared to non-VSP cases (median: 3.4 mL/implant vs. 4.2 mL/implant). Complications, revision rates, and length of stay showed no significant differences. Conclusions: The use of VSP/3DP (EPPOCRATIS) in craniomaxillofacial trauma reconstruction demonstrated operative efficiency and accurate fracture reduction in complex cases. Further studies are needed to examine the feasibility and cost-effectiveness of point-of-care VSP/3DP in trauma centers.